Novavax | NVAX - Assets


Novavax reported $955.58M in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
Adma Biologics USD 684.21M 19.03M Jun/2026
Agenus USD 172.69M 13.76M Jun/2026
AstraZeneca USD 115.83B 1.82B Jun/2026
BioCryst Pharmaceuticals USD 557.85M 92.8M Jun/2026
Cassava Sciences USD 108.37M 9.99M Mar/2026
Geron USD 519.01M 15.11M Jun/2026
GlaxoSmithKline GBP 61.74B 1.13B Jun/2026
MannKind USD 732.3M 12.1M Jun/2026
Merck USD 129.8B 1.12B Jun/2026
Minerva Neurosciences USD 97.97M 69.88M Dec/2025
Moderna USD 10.96B 527M Jun/2026
Novartis USD 118.53B 7.58B Mar/2026
Novavax USD 955.58M 87.59M Jun/2026
Pfizer USD 201.13B 6.49B Jun/2026
Sanofi EUR 129.06B 1.04B Jun/2026
Sarepta Therapeutics USD 3.19B 9.58M Jun/2026
TG Therapeutics USD 1.64B 110.79M Jun/2026